鲁索替尼在抗逆转录病毒治疗成人HIV感染者中的随机试验
结果显示鲁索替尼耐受性良好,但未显著降低血浆 IL-6 水平,却显著减少了 CD4+ T 细胞中 HLA-DR/CD38 和 Bcl-2 的表达。
要点
- 鲁索替尼 10 mg 每日两次联合 ART 治疗 5 周在病毒学抑制的 HIV 感染者中耐受性良好。
- 鲁索替尼未显著降低血浆 IL-6 水平,基线 IL-6 水平正常。
- 鲁索替尼显著降低 CD4+ T 细胞免疫激活标志物 HLA-DR/CD38 和细胞存活标志物 Bcl-2。
核心结论
- 在健康、病毒学抑制的 HIV 感染者中,鲁索替尼耐受性良好,但未显著降低正常的基线 IL-6 水平。
- 鲁索替尼显著降低了免疫激活和细胞存活标志物。
- 未来 Jak 抑制剂研究应针对尽管抑制性 ART 但仍有残余炎症的 HIV 感染者。
研究设计与样本
- ACTG A5336 是一项开放标签、多中心、随机对照试验。
- 参与者按 2:1 随机分配至鲁索替尼 10 mg 每日两次联合稳定 ART 治疗 5 周组或单用 ART 组,按依非韦伦使用分层。
- 纳入标准:ART 抑制 ≥2 年、无合并症、CD4+ T 细胞 >350/µL。
主要发现
- 主要安全性事件在鲁索替尼组发生率为 2.5%(1 名参与者),对照组为 0%(P = .67)。
- 3 名参与者(7.5%)提前终止鲁索替尼。
- 第 5 周时,鲁索替尼组与对照组的 IL-6 平均倍数变化为 0.93 vs 1.10(P = .18)。
- 可溶性 CD14 平均倍数变化:鲁索替尼组 0.96 vs 对照组 1.08;相对倍数变化 0.96(90% CI,.90-1.02)。
- 鲁索替尼降低了表达 HLA-DR/CD38 的 CD4+ T 细胞(平均差异 -0.34% [90% CI,-.66% 至 -.12%])和表达 Bcl-2 的 CD4+ T 细胞(平均差异 -3.30% [90% CI,-4.72% 至 -1.87%])。
临床怎么用
- 对于病毒学抑制且无残余炎症的 HIV 感染者,鲁索替尼 5 周治疗未显示降低 IL-6 的获益。
- 鲁索替尼可降低免疫激活和细胞存活标志物,但需在残余炎症人群进一步研究。
局限性
- 纳入人群为健康、病毒学抑制且基线 IL-6 正常的感染者,可能限制对残余炎症人群的推论。
- 开放标签设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inflammation is associated with end-organ disease and mortality for people with human immunodeficiency virus (PWH). Ruxolitinib, a Jak 1/2 inhibitor, reduces systemic inflammation for individuals without human immunodeficiency virus (HIV) and HIV reservoir markers ex vivo. The goal of this trial was to determine safety and efficacy of ruxolitinib for PWH on antiretroviral therapy (ART). METHODS: AIDS Clinical Trials Group (ACTG) A5336 was an open-label, multisite, randomized controlled trial (RCT). Participants were randomly assigned (2:1) using centralized software to ruxolitinib (10 mg twice daily) plus stable ART for 5 weeks vs ART alone, stratified by efavirenz use. Eligible participants were suppressed on ART for ≥2 years, without comorbidities, and had >350 CD4+ T cells/µL. Primary endpoints were premature discontinuation, safety events, and change in plasma interleukin 6 (IL-6). Secondary endpoints included other measures of inflammation/immune activation and HIV reservoir. RESULTS: Sixty participants were enrolled from 16 May 2016 to 10 January 2018. Primary safety events occurred in 2.5% (1 participant) for ruxolitinib and 0% for controls (P = .67). Three participants (7.5%) prematurely discontinued ruxolitinib. By week 5, differences in IL-6 (mean fold change [FC], 0.93 vs 1.10; P = .18) and soluble CD14 (mean FC, 0.96 vs 1.08; relative FC, 0.96 [90% confidence interval {CI}, .90-1.02]) levels for ruxolitinib vs controls was observed. Ruxolitinib reduced CD4+ T cells expressing HLA-DR/CD38 (mean difference, -0.34% [90% CI, -.66% to -.12%]) and Bcl-2 (mean difference, -3.30% [90% CI, -4.72% to -1.87%]). CONCLUSIONS: In this RCT of healthy, virologically suppressed PWH on ART, ruxolitinib was well-tolerated. Baseline IL-6 levels were normal and showed no significant reduction. Ruxolitinib significantly decreased markers of immune activation and cell survival. Future studies of Jak inhibitors should target PWH with residual inflammation despite suppressive ART. CLINICAL TRIALS REGISTRATION: NCT02475655.
引用
- Marconi VC, Moser C, Gavegnano C, et al. Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus. Clin Infect Dis. 2022. PMID: 33693561. doi:10.1093/cid/ciab212
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。